International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)
about
What you should know about PR3-ANCA. An introduction.Autoantibodies in vasculitisAutoantibodies in renal diseases - clinical significance and recent developments in serological detectionNovel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodiesIndirect immunofluorescence (IIF) of normal washed peripheral blood cells to demonstrate antineutrophil cytoplasmic antibodies (ANCA)The pulmonary physician in critical care * Illustrative case 3: Pulmonary vasculitisIgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitisEpitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteinsAutoantibodies in primary sclerosing cholangitisCutaneous manifestations of Churg-Strauss syndrome: report of two cases and review of the literatureDifferentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopyDetection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis.Vasculitis--diagnosis and treatment.Clinical value of antineutrophil cytoplasmic antibodies.Laboratory testing in the evaluation and diagnosis of vasculitis.Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.Clinical aspects of primary vasculitis.Clinical management and treatment of vasculitis.Current and emerging techniques for ANCA detection in vasculitis.Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory.PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.Testing for antineutrophil cytoplasmic antibodies.Antineutrophil cytoplasmic autoantibody in the absence of Wegener's granulomatosis or microscopic polyangiitis: implications for the surgical pathologist.Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine modelThe basis of T-cell-mediated immunity to chronic myelogenous leukemia.Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients.Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardiumPhotodynamic treatment of pooled coumarin plasma for external quality assessment of the prothrombin time.Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice.Clinical utility of ANCA tests for the dermatologist.ANCA associated pauci-immune retinal vasculitis.Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology.Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.Case report and review of minocycline-induced cutaneous polyarteritis nodosa.Classification of the vasculitides: are they clinically useful?Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management.
P2860
Q24791101-09D92738-76B7-4A50-820A-2ACDB4C9F710Q24804645-0CA90ABF-A716-42EE-960B-6AADEF35BD31Q26849664-E3DD4224-B0F1-4E65-8BF9-CF94AA762635Q27000411-7397AB17-FD1B-4C2F-974F-EE20BACE95AEQ27477862-500FC9E7-8130-4B40-AD54-2D1FE317E3CDQ27477909-93D2BFD1-3884-4C88-8362-A82B4CDE9730Q27478109-1A7BFC56-6BAE-420B-B227-6B4E4AAC954DQ27478112-8E5B0F30-E556-4C02-8C9F-AF00ADB5229FQ27489093-0CD2459D-3C9E-4B99-BE82-303AE5BB62B9Q28295728-60764529-F167-4A8A-8278-78FB5621BCF2Q28362587-1039B9EB-1011-497B-BC2B-1B70443E5625Q33712321-B91C51FC-251E-4636-986A-2505B0D52D76Q33814342-170640AA-7BC5-48B2-A770-897799166429Q34109070-80663BCF-17A0-44CC-8705-F03A7DE283BDQ34109097-EFBC31B2-477B-4F71-98D8-39317267E7A2Q34199391-EBC16BF5-58AC-4ED7-965B-3753FE3191DAQ34395155-1B441811-1D32-4D30-BE30-AEA8944E3BCAQ34395162-5D3966D9-7D80-4EB4-A258-8D0A47DF70A1Q34395174-1C60739C-CD7B-4F6D-ABAC-9DCEE51094C4Q34422614-C1861840-4693-46CB-8FD9-55EC1B05C6B7Q34477430-50A51C27-EAE8-432C-8770-0BC521A7E5D4Q34514665-DA993A51-40A1-49AF-80A3-B32FEA102239Q34514787-939C79FE-5F14-4FE7-A89A-05C9B0BD5F79Q34569292-41B7EE44-5CA9-47AD-A177-87646F092549Q34571110-C6B4D245-E6AD-4E93-90B1-33E69D4AE374Q34796025-A9796437-78F8-40D7-8089-456DFE413F81Q34853086-29FF5D6F-B5B9-4224-9203-6EE3014E74C2Q35022552-542BA004-140F-4326-8797-30235155E208Q35038822-7D64E068-616A-4F18-B178-DD7CE68DAB54Q35395166-21BD272E-E77C-44ED-B240-B370B9F3BE8AQ35396591-7E422502-C55A-4DA9-9356-F27A5467AD9FQ35555099-BAA11167-51A8-4019-944C-B97FAF6B39D6Q35587408-5C8472EF-261B-469E-A7C8-C82EDF156917Q35592429-9175DD16-5A89-44C0-9696-CF5469DE03B2Q35593169-DF2DDCB0-10B6-4640-A1D1-E3A9AFA79605Q35743185-F957FE5C-E079-4089-BE0C-AC66D81A154AQ35923750-9F4D5575-A86A-4613-93CE-CC9A63F0D2CCQ36149845-D55CF269-BAC6-487A-8654-96BC08C02C94Q36208055-784E6E7E-349E-4399-8893-261EFADBE30DQ36234282-4BD06F80-4BDC-426C-828E-9549B9244E86
P2860
International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@ast
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@en
International Consensus Statem ...... trophil Cytoplasmic Antibodies
@nl
type
label
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@ast
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@en
International Consensus Statem ...... trophil Cytoplasmic Antibodies
@nl
prefLabel
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@ast
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@en
International Consensus Statem ...... trophil Cytoplasmic Antibodies
@nl
P2093
P356
P1476
International Consensus Statem ...... Cytoplasmic Antibodies (ANCA)
@en
P2093
Jennette JC
Paspaliaris B
P304
P356
10.1093/AJCP/111.4.507
P407
P577
1999-04-01T00:00:00Z